SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorSuzhou Suncadia Biopharmaceuticals Co., Ltd.
About this trial
This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.
Eligibility criteria
Qualifiers
Subjects must voluntarily join this study, sign the informed consent form, have good compliance and be able to cooperate with the follow-up.
Female, aged 18-75 years old.
Expected survival ≥ 12 weeks.
Normal function of vital organs.
Disqualifiers
Previous or concomitant other malignancies.
Severe bone damage caused by bone metastasis from tumours.
Presence of active autoimmune disease or history of autoimmune disease with possible recurrence.
Those with active tuberculosis.
Trial design
Treatments tested in this trial
- SHR-A1811
- Adebelimab injection
- Bevacizumab injection
- SHR-8068
- Cisplatin injection
- Carboplatin injection
Treatment groups
100 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov